• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

FDA advisory committee recommends approval of Janssen’s intranasal esketamine

The FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management (DSaRM) Advisory Committee met on February 12, 2019 to consider Janssen’s NDA for its esketamine nasal spray for the treatment of treatment-resistant depression in adults and voted in favor of approval.

On the question, “Has the Applicant provided substantial evidence of the effectiveness of esketamine for the treatment of treatment-resistant depression?” the vote was 14 yes, 2 no, with one abstention.

On the question, “Has the Applicant adequately characterized the safety profile of esketamine for the treatment of treatment-resistant depression?” the vote was 15 yes, 2 no.

Janssen, which is now calling the nasal spray “Spravato,” submitted the NDA for the product in September 2018. The PDUFA date for the FDA to complete its review of the Spravato NDA is March 4, 2019.

Janssen Research & Development Global Head, Neuroscience Therapeutic Area, Husseini K. Manji commented, “We are pleased with the advisory committees’ vote and their recommendation to approve Spravato as a potential therapy for adults living with treatment-resistant depression. Our comprehensive research program for esketamine nasal spray supports a positive benefit-risk profile for adults with treatment-resistant depression.”

Read the Janssen press release.

Share

published on February 12, 2019

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews